DEPOSITIONS AND TESTIMONY:

Affidavit (with H. Ware) in the matter of U.S. vs. Western Electric Co. and American Telephone and Telegraph Company, U.S. District Court for the District of Columbia, Civil Action No. 82-0192-HHG, supporting the "Reply of BellSouth Corporation in Support of its Motion for Generic Wireless Relief," filed September 2, 1994.

Affidavit on behalf of BellSouth Corporation before the Federal Communications Commission in the matter of *Amendment of the Commission's Rules to Establish New Personal Communications Services*, GEN Docket No. 90-314, filed August 30, 1994.

Affidavit (with H. Ware) in the matter of *U.S. vs. Western Electric Co. and American Telephone and Telegraph Company*, U.S. District Court for the District of Columbia, Civil Action No. 82-0192-HHG, supporting "BellSouth Corporation's Opposition to AT&T's Motion for a Waiver of Section I(D) of the Decree Insofar as it Bars the Proposed AT&T-McCaw Merger," filed June 28, 1994.

Affidavit, Reply Affidavit and Affidavit (with H. Ware) on behalf of BellSouth Corporation before the Federal Communications Commission in the matter of AT&T-McCaw Merger, In re Applications of American Telephone and Telegraph Company and Craig O. McCaw For Consent to the Transfer of Control of McCaw Cellular Communications, Inc. and its Subsidiaries, File No. ENF-93-44, filed November 1, 1993, January 18, 1994 and June 20, 1994, respectively.

Testimony on behalf of Alpha 1 Biomedicals, Inc. in the matter of Alpha 1 Biomedicals, Inc. vs. SciClone Pharmaceuticals, Inc., American Arbitration Association, No. 74 E 113 00902 93, February 11-12, 1994.

Deposition on behalf of Alpha 1 Biomedicals, Inc. in the matter of Alpha 1 Biomedicals, Inc. vs. SciClone Pharmaceuticals, Inc., American Arbitration Association, No. 74 E 113 00902 93, January 13, 1994.

Declaration on behalf of Alpha 1 Biomedicals, Inc. in the matter of SciClone Pharmaceuticals, Inc. vs. Alpha 1 Biomedicals, Inc., U.S. District Court for the Northern District of California, Civil Action No. C93-3464-CAL, October 1, 1993.

Testimony on behalf of American Cyanamid Company in the matter of *Mylan Pharmaceuticals*, *Inc. vs. American Cyanamid Company vs. Roy McKnight*, U.S. District Court for the Northern District of West Virginia, Civil Action No. 90-0121-C(S), September 21-23, 1993.

Deposition on behalf of American Cyanamid Company in the matter of *Mylan Pharmaceuticals*, *Inc. vs. American Cyanamid Company vs. Roy McKnight*, U.S. District Court for the Northern District of West Virginia, Civil Action No. 90-0121-C(S), August 6-7, 1993.

Affidavit on behalf of American Cyanamid Company in the matter of Mylan Pharmaceuticals, Inc. vs. American Cyanamid Company vs. Roy McKnight, U.S. District Court for the Northern District of West Virginia, Civil Action No. 90-0121-C(S), January 20, 1993.



Testimony on behalf of Dornier Medical Systems, Inc. in the matter of *Technical Resource Services*, *Inc.* vs. *Dornier Medical Systems*, *Inc.*, U.S. District Court for the Middle District of Florida Orlando Division, Civil Action No. 91-762-CIV-ORL-19, June 22-23, 1993.

Deposition on behalf of Dornier Medical Systems, Inc. in the matter of *Technical Resource Services*, *Inc.* vs. *Dornier Medical Systems*, *Inc.*, U.S. District Court for the Middle District of Florida Orlando Division, Civil Action No. 91-762-CIV-ORL-19, January 26, 1993.

Declaration and Reply Declaration on behalf of Xoma Corporation in the matter of Xoma Corporation vs. Centocor, Inc., U.S. District Court for the Northern District of California, Civil Action No. C-90-1129-RHS, January 8, 1992 and March 7, 1992, respectively.

Deposition on behalf of Xoma Corporation in the matter of *Xoma Corporation vs. Centocor, Inc.*, U.S. District Court for the Northern District of California, Civil Action No. C-90-1129-RHS; and "Certain Monoclonal Antibodies Used for Therapeutically Treating Humans Having Gram Negative Bacterial Infections," U.S. International Trade Commission, Investigation No. 337-TA-323, June 27, 1991.

Affidavit (with C. Jackson) in the matter of *U.S. vs. Western Electric Co. and American Telephone and Telegraph Company*, U.S. District Court for the District of Columbia, Civil Action No. 82-0192-HHG, supporting the "Request by BellSouth Corporation for a Waiver of the Modification of Final Judgment to Allow BellSouth Corporation to Provide Integrated MultiLATA Cellular Service," filed May 9, 1991.

Testimony (written) on behalf of Eighteen Vermont Utilities before the Federal Energy Regulatory Commission in the matter of *Northeast Utilities Service Company (Re: Public Service Company of New Hampshire)*, Docket Nos. EC90-10-000, ER90-143-000, ER90-144-000, ER90-145-000 and EL90-9-000, May 25, 1990.

Deposition on behalf of Ortho Pharmaceutical Corp. in the matter of *Ortho Pharmaceutical Corp. vs. Amgen, Inc.*, Endispute Arbitration, August 22 and September 15, 1989.

Deposition on behalf of McGraw Edison Company in the matter of Augustus Oliviere vs. McGraw Edison Company, et al, U.S. District Court for the District of Columbia, Civil Action No. 87-600-JHP, November 11, 1987.

CONSULTING REPORTS:

"Answers to the DOJ Questions on the Competitive Effects of the PMA Undertaking," prepared for the Pharmaceutical Manufacturers Association, April 1993.

"Profile of the Health Care System in Canada" and "Reform of the Health Care System in Canada," (with C. Salisbury), prepared as part of the volume *The Health Care System in Canada* for the project Financing Health Care with Particular Reference to Medicines, April 1993.



"The Consequences of Pharmaceutical Product Patenting: A Critique," prepared for the Pharmaceutical Manufacturers Association, December 1992.

"Review of the GAO Report: Prescription Drugs: Companies Typically Charge More in the United States Than in Canada," prepared for a research-based pharmaceutical firm, November 1992.

"Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation," (with R. Rapp), prepared for the Pharmaceutical Manufacturers Association, July 1992 (NERA Working Paper No. 16).

"The Commission Should Close Its Investigation of Lamar's Acquisition of Metro," (with J. McDavid and C. Lamar), prepared for a client involved in a FTC investigation, May 1992.

"Economics of the Research-Based Pharmaceutical Industry," (with C. Salisbury), prepared for the Pharmaceutical Manufacturers Association, February 1992.

"An Analysis of a Proposed Acquisition by R.P. Scherer International Corporation," prepared to help a client assess the competitive impact of a proposed acquisition in the U.S. and certain foreign countries, September 1991.

"Public Disclosure of Bids and Bidders," (with M. Bidwell and H. Nalbantian), prepared for New York Telephone Company, June 1991.

"Benefits and Costs of Intellectual Property Protection in Developing Countries," (with R. Rapp), prepared for a group of pharmaceutical firms interested in including intellectual property rights in the GATT, June 1990 (NERA Working Paper No. 3).

"Hospital Rate Regulation in Maryland: The Effect on Howard County General Hospital," (with C. Groszer and L. Nordgulen), prepared to help a client identify methodological and statistical problems with the approach to hospital rate setting in Maryland, April 1989.

"Update on Utility Competitive Bidding Programs," (with L. Nordgulen), prepared for the Energy Research Group, February 1989.

"Bidding Theory and the Baseball Player Market," prepared for a client concerned about compensation issues in professional sports, November 1988.

"The Bulk Power Coordination Services Market in Northern California: A Competitiveness Assessment," (with M. Rosenzweig and L. Nordgulen), prepared for a U.S. investor-owned utility, July 1988.

"An Analysis of the Westinghouse/ASEA-Brown Boveri Joint Ventures," prepared for a client concerned about combinations of firms in electric equipment markets, July 1988.

"Legal and Economic Theories of Contracts and Contract Discharge," prepared as background in *Wendy's vs. Pepsico* litigation, December 1987.




"A Guide to the Economics of Bidding and Auctioning Processes," prepared for the Energy Research Group, November 1987.

"Analysis of Market Power Using SAC," prepared as background in *ETSI Pipeline Project vs. Burlington Northern, Inc. et al*, U.S. District Court for the Eastern District of Texas, Civil Action No. B-84-979, October 1987.

September 1994





1993 CELLULAR RATES IN THE TOP 100 MSAs REGRESSION OUTPUT

(Dependent Variable (Y): Minimum Rate for 125 MOUs)


Constant	51.02
Standard Error of Y Estimate	9.138
R Squared	0.357
Number of Observations	200
Degrees of Freedom	186

Independent Variables	Estimates	T-Statistic
Income per Capita (\$)	0.001	1.89
MSA population (Millions)	1.160	3.51
Both RBOC	(3.220)	(1.56)
No RBOC	(1.390)	(0.78)
Regulation	`8.625 [′]	`5.18 [´]
Operator Dummies:		
Ameritech	(4.796)	(1.22)
Bell Atlantic	2.803	1.05
BellSouth	(1.534)	(0.61)
NYNEX	5.715	1.71
Southwestern	(2.081)	(0.62)
US West	9.980	3.01
Airtouch	2.040	0.79
McCaw	4.281	1.98

() negative

Note: For all variables other than Income per Capita and MSA population, the variable unit is equal to either 0 or 1.

Source: Derived from Cellular Rates, Paul Kagan and Associates, Inc., January 1994, Vol. 1, pp 47-48.



DEMOGRAPHICALLY SIMILAR CITIES TO NEW ORLEANS AND BATON ROUGE

							Percent	of Earnings By I	ndustry		
		Populatio	n					Prof. Serv.,			
City Group/			Per Square	F	Per Capita		Goods-	Retail, &		Govern-	Civilian
Three-City Comparison	<u>Total</u>	Rank	Kilometer_	_	Income	Farm	Related	Other [1]	Services	ment	Labor Force
					(Dollars)	***************************************		(Percent)			
	(1)	(2)	(3)		(4)	(5)	(6)	(7)	(8)	(9)	(10)
New Orleans, LA	1,294,991	40	147	\$	16,959	0.2 %	21.8 %	33.0 %	29.6 %	15.4 %	595,152
Orlando, FL	1,268,774	43	140		17,832	1.3	17.8	32.3	35.1	13.5	726,934
Jacksonville, FL	933,637	58	137		17,938	0.3	15.0	38.5	24.8	21.5	470,430
Indianapolis, IN	1,405,567	35	154		19,845	0.2	29.5	32.0	24.1	14.2	745,672
Batan Dayas I A	E27 704	89	131		16,781	0.2 0	30.0 %	20.4 0	2478	40 O W	202.000
Baton Rouge, LA	537,781			Þ	•	0.3 %		26.1 %	24.7 %	18.9 %	283,269
Columbia, SC	463,866	99	123		17,706	0.4	17.4	30.7	23.5	28.0	248,551
Chattanooga, TN-GA	428,575	106	91		16,801	0.4	na	na	23.7	18.3	209,582
Birmingham, AL	849,195	67	103		18,210	0.6	20.9	36.8	27.2	14.5	417,808

na not available

[1] Total service related and other less services.

Source:

1994 County and City Extra: Annual Metro, City and County Data Book

Table B.

DIFFERENCE IN BELLSOUTH CELLULAR LOWEST RATES FOR SELECTED REGULATED CITY AND UNREGULATED THREE-CITY COMPARISON [1] FOR VARYING MINUTES OF MONTHLY USAGE

Lowest Monthly Rate as Reported by Minutes of Use

		10	25	50		75	_	100_	125	<u>.</u>	150		175		200	3	225		50 llars)	2	75	30	0	325	3	350	40	0	450		500	600	<u>)</u>	800		1000	-	150	<u>)</u>	2000	
		(1)	(2)	(3)		(4)		(5)	(6)	(7)		(8)		(9)		(10)		11)	(1	12)	(1:	3)	(14)	((15)	(16	6)	(17)		(18)	(19)	(20)		(21)		(22		(23)	
New Orleans Three-City Comparison [2] Difference	\$	29 26 3	\$ 34 33	\$ 43 40 3	\$	50 47 3	\$	50 <u>53</u> (3)	\$ 60 59 \$ 1	•	69 <u>67</u>	\$	79 <u>75</u>	s	88 82 6	s	98 88 10	-	99 95	\$ 10 10	07 00 7	\$ 11 10 \$ 1	- ,	123 110	•	131 117 14	\$ 14 12 \$ 2	ī	\$ 155 <u>138</u> \$ 17		170 150 20	\$ 195 165 \$ 30	5	253 212	\$	311 257 54	\$	456 361 88		601 480 121	
Baton Rouge Three-City Comparison [3] Difference	5	39 26 13	\$ 44 33 11	\$ 53 43 10	5	53 52 1	s s	57 56 1	\$ 65 57 \$ 8	•	74 64 10	\$ \$	83 73 10	\$	92 82 10	\$	99 85 14		99 <u>89</u> 10		07 97 10	\$ 11 10 \$ 1	-	124 112 12	•	132 120 12	\$ 14' 13' \$ 1-	9 :	\$ 155 142 \$ 13	\$ \$	171 144 27	\$ 195 165 \$ 30	5 \$	255 190 65	i	315 236 79	\$	469 357	5	615 489 126	

Source: Derived from BellSouth Cellular Pricing History by City, and 1994 County and City Extra, Annual Metro, City and County Data, pp. 738, 766, 780, and 794.

^[1] Matched cities were selected based on similarities in population size, density, and income.

^[2] Weighted average (by population) of the lowest cellular rates (access and airtime) offered by BellSouth in Jacksonville, Orlando, and Indianepolis.
[3] Weighted average (by population) of the lowest cellular rates offered by BellSouth in Birmingham, Chattanooga, and Columbia.

ESTIMATED CELLULAR PENETRATION RATES FOR NEW ORLEANS AND BATON ROUGE AND THEIR RESPECTIVE THREE-CITY COMPARISON GROUPS

City Group/ Three-City Comparison [1]	Estimated Cellular Penetration [2] (Percent) (1)
New Orleans, LA Orlando, FL Jacksonville, FL Indianapolis, IN	7.38 % 9.89 7.52 8.01 [3]
Baton Rouge, LA Columbia, SC Chattanooga, TN-GA Birmingham, AL	9.65 % 10.70 na 10.20

na not available

- [1] Comparison based on the following criteria: population, per capita income, industry earnings and civilian labor force.
- [2] Based on 1994 Market Share Estimate, unless otherwise noted.
- [3] Based on 1992 Market Share Esimate.

Source: Data provided by BellSouth.

CERTIFICATE OF SERVICE

I, Shelia L. Robertson, hereby certify that on this 19th day of September 1994, copies of the foregoing "Comments of BellSouth Corporation in Opposition To Louisiana Public Service Commission's Petition To Continue Rate Regulation of Commercial Mobile Radio Services" were served on the following:

Michael F. Altschul Vice President, General Counsel Cellular Telecommunications Industry Association 1250 Connecticut Avenue, N.W, Suite 200 Washington, DC 20036

Brian A. Eddington General Counsel and Assistant Secretary Carolyn L. DeVitis Senior Attorney Louisiana Public Service Commission One American Place, Suite 1630 Baton Rouge, LA 70825

Paul L. Zimmering William L. Geary, Jr. Stephanie D. Shuler Stone, Pigman, Walther, Wittmann & Hutchinson 546 Carondelet Street New Orleans, LA 70130

Rosalind Allen
Acting Chief, Land Mobile &
Microwave Division
Federal Communications Commission
2025 M Street, N.W., Room 5202E
Washington, DC 20554

Gina Harrison Attorney, Land Mobile & Microwave Division Federal Communications Commission 2025 M Street, N.W., Room 5202E Washington, DC 20554

Shelia L. Robertson